Hinge Health (HNGE) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Hinge Health published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Hinge Health reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Hinge Health reports one segment and does not split revenue by program in its release or 10-Q.
• Hinge Health went public in May 2025. Its 2025 per-share results include very large stock-based compensation recognized around the IPO ($625.8 million in the first nine months of 2025), so year-over-year per-share comparisons are distorted.
• Hinge Health acquired Cylinder Health, a virtual-first digestive healthcare company, on August 31, 2026 for $105.8 million.

Source: Hinge Health Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

From the earnings release

In its Q3 2026 release, Hinge Health said:

“Q4 2026: We expect revenue to be between $249 million and $251 million, reflecting year-over-year growth of 46% at the midpoint.”

“We expect non-GAAP income from operations to be between $81 million and $83 million, reflecting year-over-year growth of 71% and non-GAAP operating margin of 33% at the midpoint, a ~470 bps increase over Q4 2025.”

“Full Year 2026: We are raising our revenue guidance to be between $879 million and $881 million, reflecting year-over-year growth of 50% at the midpoint.”

“We are raising our non-GAAP income from operations guidance to be between $266 million and $268 million, reflecting year-over-year growth of 123% and non-GAAP operating margin of 30% at the midpoint, a ~1,000 bps increase over 2025.”

Source: Hinge Health Q3 2026 release, Nov 2, 2026.

This is the company's own guidance as of Nov 2, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the HNGE forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted net income (loss) per share attributable to common stockholders, each as first reported in that quarter's release.

We do not hold a confirmed date for Hinge Health's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

Hinge Health sells digital care programs for musculoskeletal (MSK) pain, migraine and, after its Cylinder Health acquisition, gastrointestinal conditions, paid for by employers and health plans. Revenue was $235.0 million in Q3 2026, up 52% from $154.2 million. Clients pay either a fixed annual fee or a variable fee based on member engagement, billed after a member's first billable activity or as cohort milestones are reached. (Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026; Hinge Health Form 10-Q for the quarter ended September 30, 2026, Nov 9, 2026)

Most of Hinge Health's growth came from clients it already had. The 10-Q says revenue from new clients contracted in a year is largely recognized the following year, so the Q3 2026 increase came mainly from clients contracted in 2025 or earlier, which kept members and added more of them. Clients rose 28% to 3,270 from 2,560. (Hinge Health Form 10-Q for the quarter ended September 30, 2026, Nov 9, 2026; Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026)

Hinge Health reaches most clients through partners such as health plans. Revenue from client contracts entered into through partners was 86% of total revenue in Q3 2026, against 83% a year earlier, according to the 10-Q. Most revenue comes from self-insured employers, and Hinge Health is adding fully-insured employers and Medicare Advantage plans through those partners. (Hinge Health Form 10-Q for the quarter ended September 30, 2026, Nov 9, 2026)

Billings run ahead of revenue and peak in the second quarter, when Hinge Health bills most clients signed the year before. LTM calculated billings rose 54% to $960.3 million at September 30, 2026. GAAP gross margin was 87%, up from 82%. (Hinge Health Form 10-Q for the quarter ended September 30, 2026, Nov 9, 2026; Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026)

Hinge Health earned net income of $57.4 million in Q3 2026, or $0.66 per diluted share, against a loss of $1.8 million, or $0.02 per share, a year earlier. GAAP income from operations was $50.3 million, a 21% margin, against a $6.1 million loss. Non-GAAP diluted EPS was $0.71, up from $0.32. (Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026)

Hinge Health's non-GAAP figures exclude stock-based compensation ($19.5 million in the quarter), related employer payroll taxes ($3.5 million), amortization of intangible assets and acquisition-related expenses, less the tax effect of those adjustments ($23.0 million). The quarter also had an income tax benefit of $3.7 million, which the 10-Q ties to excess tax benefits from stock-based compensation and the release of valuation allowances tied to deferred tax liabilities on acquired intangible assets. (Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026; Hinge Health Form 10-Q for the quarter ended September 30, 2026, Nov 9, 2026)

Diluted weighted average shares were 86.5 million. Hinge Health repurchased 295,972 shares for $25.2 million in the quarter under a program its board approved on November 10, 2025 for up to $250 million. (Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026; Hinge Health Form 10-Q for the quarter ended September 30, 2026, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Hinge Health gives quarterly and full-year guidance in its release. For Q4 2026 it expects revenue of $249 million to $251 million, 46% growth at the midpoint, and non-GAAP income from operations of $81 million to $83 million. It raised full-year 2026 revenue guidance to $879 million to $881 million, 50% growth at the midpoint, and non-GAAP income from operations to $266 million to $268 million, a 30% margin at the midpoint. (Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026)

Hinge Health does not guide GAAP operating income, citing the variability of stock-based compensation and acquisition items. CEO Daniel Perez described a record sales season, with the MSK Care Program client base up almost 30% from a year earlier. The 10-Q says the Gastrointestinal Care Program built on Cylinder is expected to launch in 2027. (Hinge Health Q3 2026 earnings release (Form 8-K, Exhibit 99.1), Nov 2, 2026; Hinge Health Form 10-Q for the quarter ended September 30, 2026, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover Hinge Health, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Hinge Health's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning HNGE is on is HNGE a buy or a sell?, what analysts expect next is on the HNGE forecast, and what the company does is on the Hinge Health (HNGE) stock page.

Every number on this page can be traced to a document Hinge Health published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.